NASDAQ: CLOVClover Health Investments Corp Stock
$0.93+0.00 (+0%)
Updated Nov 29, 2023
CLOV Price
$0.93
Fair Value Price
$1.33
Market Cap
$452.53M
52 Week Low
$0.71
52 Week High
$1.63
P/E
-1.97x
P/B
1.41x
P/S
0.21x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.42B
Earnings
-$226.94M
Gross Margin
9%
Operating Margin
-9.36%
Profit Margin
-9.4%
Debt to Equity
2.29
Operating Cash Flow
-$96M
Beta
1.58
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CLOV Overview
Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.
Zen Score
–
Industry Average (38)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CLOV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLOV ($0.93) is undervalued by 30.03% relative to our estimate of its Fair Value price of $1.33 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CLOV ($0.93) is significantly undervalued by 30.03% relative to our estimate of its Fair Value price of $1.33 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CLOV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CLOV due diligence checks available for Premium users.
Be the first to know about important CLOV news, forecast changes, insider trades & much more!
CLOV News
Valuation
CLOV fair value
Fair Value of CLOV stock based on Discounted Cash Flow (DCF)
Price
$0.93
Fair Value
$1.33
Undervalued by
29.88%
CLOV ($0.93) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CLOV ($0.93) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CLOV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CLOV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.97x
Industry
19.72x
Market
29.48x
CLOV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.41x
Industry
3.07x
CLOV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CLOV's financial health
Profit margin
Revenue
$482.1M
Net Income
-$41.5M
Profit Margin
-8.6%
CLOV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CLOV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.1B
Liabilities
$737.9M
Debt to equity
2.29
CLOV's short-term assets ($915.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLOV's short-term assets ($915.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLOV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.8M
Investing
-$20.3M
Financing
-$2.0M
CLOV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLOV vs Healthcare Plan Stocks
Clover Health Investments Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.